Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Phase 1 IO-PDT of NSCLC with Photofrin has New Start Date

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Feb 03, 2021 1:07pm

130 Views

Post# 32459566

RE:Phase 1 IO-PDT of NSCLC with Photofrin has New Start Date

Eoganacht wrote: Roswell Park first posted this 12 patient, phase 1 trial on clinicaltrials.gov on Sep. 19, 2018 and no patients have been recruited yet. The new estimated start date is February 28, 2021, and estimated completion date February 28, 2023. The light dosimetry system to be used is Lumeda's DigiLum and the principal investigator is thoracic surgeon, Dr. Saikrishna Yendamuri.

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

There may be another phase 1 trial of this kind planned, but using TLD1433 instead of photofrin, to start in Q2-21. If they decide to use TLD1433, we should hear about it some time in Q1-21.

Lumeda Clinical Studies List